Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
February 07, 2025 07:54 ET
|
Novo Nordisk A/S
Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo...
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
February 07, 2025 02:45 ET
|
Novo Nordisk A/S
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 –...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
February 06, 2025 04:12 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
Novo Nordisk files annual report with the SEC
February 05, 2025 07:36 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC), incorporating by...
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
February 05, 2025 01:30 ET
|
Novo Nordisk A/S
Bagsværd, 5 February 2025 - Financial report for the period 1 January 2024 to 31 December 2024 ...
Novo Nordisk A/S - share repurchase programme
February 04, 2025 07:57 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 4 February 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
January 27, 2025 08:05 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
January 24, 2025 05:19 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once...
Novo Nordisk A/S - share repurchase programme
January 20, 2025 09:32 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
January 17, 2025 07:11 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial...